niacin has been researched along with Disease Models, Animal in 92 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current study aimed to investigate the potential impact of niacin on colitis-induced depressive-like behavior in rats." | 8.31 | Niacin modulates depressive-like behavior in experimental colitis through GPR109A-dependent mechanisms. ( Abd El-Haleim, EA; Khayyal, MT; Mohamed, SS; Wadie, W, 2023) |
| "Niacin deficiency causes pellagra, the symptoms of which include dermatitis, diarrhoea and dementia." | 8.12 | Effect of niacin supplementation on nausea-like behaviour in an isoniazid-induced mouse model of pellagra. ( Ishikawa, T; Kuroita, T; Kuronuma, K; Natsumi, S; Yoshioka, T, 2022) |
| "Niacin has been widely used as an antihyperlipidemic drug, but the flushing effect restricted its clinical application." | 7.96 | Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. ( Cai, W; Chen, J; Jiang, Y; Jin, M; Liu, P; Pi, R; Yan, J; Yao, M, 2020) |
| " Given this gene's role in niacin metabolism and the evidence for niacin deficiency provoking schizophrenialike symptoms in neuropsychiatric diseases such as pellagra and Hartnup disease, these results suggest that the rs10866912 genotype and niacin status may have implications for schizophrenia susceptibility and treatment." | 7.91 | Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study. ( Bakshi, A; Brown, MA; Filippich, C; Fowdar, J; Giacomotto, J; Gratten, J; Gundugurti, PR; Hemani, G; Holliday, EG; Jegadeesan, J; John, S; Jorde, LB; McLean, D; McRae, A; Mowry, BJ; Nagasundaram, A; Nancarrow, D; Nertney, D; Nyholt, DR; Padmavati, R; Patel, K; Periyasamy, S; Rajendren, P; Selvaraj, K; Smith, H; Suetani, R; Thara, R; Thirunavukkarasu, P; Tirupati, S; Vinkhuyzen, A; Wray, NR, 2019) |
| "The widely used lipid-lowering drug niacin is reported to induce hyperglycemia during chronic and high-dose treatments, but the mechanism is poorly understood." | 7.81 | Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. ( Boucher, BJ; Chen, L; Cheng, Q; Leung, PS; Li, SY; So, WY, 2015) |
| "The purpose of the current study was to investigate the protective effect of niacin on acute lung injury by the down-regulation of the nuclear factor κB (NF-κB) pathway in hemorrhagic shock (HS) rats." | 7.81 | The therapeutic effect and mechanism of niacin on acute lung injury in a rat model of hemorrhagic shock: Down-regulation of the reactive oxygen species-dependent nuclear factor κB pathway. ( Jeong, KY; Jung, YS; Kim, KS; Kwon, WY; Kye, YC; Suh, GJ, 2015) |
| "In this study we examined the effect of combination treatment of experimental stroke with Niaspan, a prolonged-release formulation of Niacin (vitamin B3), and Simvastatin, a cholesterol-lowering drug, on functional outcome, axonal damage, axonal density and the of Iba-1 immunoreactive microglia expression in the ischemic brain of rats." | 7.76 | Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome. ( Chen, J; Chopp, M; Cui, X; Lu, M; Roberts, C; Shehadah, A, 2010) |
| "To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels." | 7.76 | Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. ( Barter, PJ; Charlton, F; Rye, KA; Witting, P; Wu, BJ; Yan, L, 2010) |
| "Taurine and niacin have been previously found to block the accumulation of collagen in lung in the multidose bleomycin hamster model of pulmonary fibrosis." | 7.69 | Dietary supplementation with taurine and niacin prevents the increase in lung collagen cross-links in the multidose bleomycin hamster model of pulmonary fibrosis. ( Blaisdell, RJ; Giri, SN; Schiedt, MJ, 1994) |
| "Heavy male Sprague-Dawley rats die of ventricular fibrillation within 2 to 3 h after isoproterenol administration." | 7.67 | Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death. ( Balazs, T; Ehrreich, SJ; el-Hage, AN; Johnson, GL, 1986) |
| " The evaluation of the side effects present shortly after dosing in the rotarod test has revealed neurotoxicity of Nic-BZA with experimentally determined TD50 value of 188." | 5.43 | Protective action of nicotinic acid benzylamide in a variety of chemically-induced seizures in mice. ( Paruszewski, R; Świąder, K; Świąder, MJ; Turski, WA; Łuszczki, JJ, 2016) |
| "Niacin was administered 3 days before the ischemia through 7 days of reperfusion." | 5.42 | Niacin ameliorates kidney warm ischemia and reperfusion injury-induced ventricular dysfunction and oxidative stress and disturbance in mitochondrial metabolism in rats. ( Fu, YH; Tai, ST; Wang, JJ; Yang, YC, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD), a leading cause of liver damage, comprises a spectrum of liver abnormalities including the early fat deposition in the liver (hepatic steatosis) and advanced nonalcoholic steatohepatitis." | 5.40 | Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML; Kukes, GD; Lambrecht, N, 2014) |
| " The current study aimed to investigate the potential impact of niacin on colitis-induced depressive-like behavior in rats." | 4.31 | Niacin modulates depressive-like behavior in experimental colitis through GPR109A-dependent mechanisms. ( Abd El-Haleim, EA; Khayyal, MT; Mohamed, SS; Wadie, W, 2023) |
| "Niacin deficiency causes pellagra, the symptoms of which include dermatitis, diarrhoea and dementia." | 4.12 | Effect of niacin supplementation on nausea-like behaviour in an isoniazid-induced mouse model of pellagra. ( Ishikawa, T; Kuroita, T; Kuronuma, K; Natsumi, S; Yoshioka, T, 2022) |
| "Niacin has been widely used as an antihyperlipidemic drug, but the flushing effect restricted its clinical application." | 3.96 | Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. ( Cai, W; Chen, J; Jiang, Y; Jin, M; Liu, P; Pi, R; Yan, J; Yao, M, 2020) |
| " Given this gene's role in niacin metabolism and the evidence for niacin deficiency provoking schizophrenialike symptoms in neuropsychiatric diseases such as pellagra and Hartnup disease, these results suggest that the rs10866912 genotype and niacin status may have implications for schizophrenia susceptibility and treatment." | 3.91 | Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study. ( Bakshi, A; Brown, MA; Filippich, C; Fowdar, J; Giacomotto, J; Gratten, J; Gundugurti, PR; Hemani, G; Holliday, EG; Jegadeesan, J; John, S; Jorde, LB; McLean, D; McRae, A; Mowry, BJ; Nagasundaram, A; Nancarrow, D; Nertney, D; Nyholt, DR; Padmavati, R; Patel, K; Periyasamy, S; Rajendren, P; Selvaraj, K; Smith, H; Suetani, R; Thara, R; Thirunavukkarasu, P; Tirupati, S; Vinkhuyzen, A; Wray, NR, 2019) |
| "Niacin is effective in treating dyslipidemias but causes cutaneous vasodilation or flushing, a side effect that limits its clinical use." | 3.81 | TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice. ( Clifton, HL; Inceoglu, B; Ma, L; Schaefer, S; Zheng, J, 2015) |
| "The widely used lipid-lowering drug niacin is reported to induce hyperglycemia during chronic and high-dose treatments, but the mechanism is poorly understood." | 3.81 | Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. ( Boucher, BJ; Chen, L; Cheng, Q; Leung, PS; Li, SY; So, WY, 2015) |
| "The purpose of the current study was to investigate the protective effect of niacin on acute lung injury by the down-regulation of the nuclear factor κB (NF-κB) pathway in hemorrhagic shock (HS) rats." | 3.81 | The therapeutic effect and mechanism of niacin on acute lung injury in a rat model of hemorrhagic shock: Down-regulation of the reactive oxygen species-dependent nuclear factor κB pathway. ( Jeong, KY; Jung, YS; Kim, KS; Kwon, WY; Kye, YC; Suh, GJ, 2015) |
| "Pellagra is a photosensitivity syndrome characterized by three "D's": diarrhea, dermatitis, and dementia as a result of niacin deficiency." | 3.79 | Prostaglandin E₂ is critical for the development of niacin-deficiency-induced photosensitivity via ROS production. ( Akira, S; Ikenouchi-Sugita, A; Kabashima, K; Kuroda, E; Miyachi, Y; Nakahigashi, K; Nakamura, J; Nakamura, M; Nakayama, Y; Narumiya, S; Nomura, T; Sakabe, J; Sugita, K; Tokura, Y; Uematsu, S; Yoshioka, H, 2013) |
| "Inhibition of sEH markedly reduces niacin-induced flushing in this model without an apparent effect on the response to PGD2." | 3.78 | Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice. ( Clifton, HL; Hammock, BD; Hegedus, C; Inceoglu, AB; Schaefer, S; Yang, J, 2012) |
| "To induce endotoxemia in rats, lipopolysaccharide (Escherichia coli, O26:B6) at a dosage of 10 mg/kg was injected into a tail vein and 10 mins later, vehicle, a low dose of niacin (360 mg/kg), or a high dose of niacin (1180 mg/kg) was administered once through an orogastric tube, respectively." | 3.77 | Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-κB pathway. ( Kim, KS; Kwak, YH; Kwon, WY; Suh, GJ, 2011) |
| "Niaspan, an extended-release formulation of Niacin (vitamin B3), has been widely used to increase high density lipoprotein (HDL) cholesterol and to prevent cardiovascular diseases and stroke." | 3.76 | Niaspan treatment induces neuroprotection after stroke. ( Chen, J; Chopp, M; Cui, Y; Ion, M; Kapke, A; Roberts, C; Shehadah, A; Zacharek, A, 2010) |
| "In this study we examined the effect of combination treatment of experimental stroke with Niaspan, a prolonged-release formulation of Niacin (vitamin B3), and Simvastatin, a cholesterol-lowering drug, on functional outcome, axonal damage, axonal density and the of Iba-1 immunoreactive microglia expression in the ischemic brain of rats." | 3.76 | Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome. ( Chen, J; Chopp, M; Cui, X; Lu, M; Roberts, C; Shehadah, A, 2010) |
| "To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels." | 3.76 | Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. ( Barter, PJ; Charlton, F; Rye, KA; Witting, P; Wu, BJ; Yan, L, 2010) |
| "Niacin increases HDL and promotes angiogenesis, which may contribute to improvement of functional outcome after stroke." | 3.74 | Niaspan increases angiogenesis and improves functional recovery after stroke. ( Chen, J; Chopp, M; Cui, X; Feldkamp, CS; Jiang, H; Kapke, A; Lu, M; Roberts, C; Zacharek, A; Zhang, C, 2007) |
| "Our data suggest that at least one drug commonly used to treat schizophrenia (haloperidol) can interfere with the vasodilatory response to NA." | 3.71 | An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. ( Ross, BM; Seeman, M; Turenne, SD, 2001) |
| "Taurine and niacin have been previously found to block the accumulation of collagen in lung in the multidose bleomycin hamster model of pulmonary fibrosis." | 3.69 | Dietary supplementation with taurine and niacin prevents the increase in lung collagen cross-links in the multidose bleomycin hamster model of pulmonary fibrosis. ( Blaisdell, RJ; Giri, SN; Schiedt, MJ, 1994) |
| "Heavy male Sprague-Dawley rats die of ventricular fibrillation within 2 to 3 h after isoproterenol administration." | 3.67 | Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death. ( Balazs, T; Ehrreich, SJ; el-Hage, AN; Johnson, GL, 1986) |
| " A range of dosing regimens was analyzed and predictions made for optimizing NiAc delivery to minimize FFA exposure." | 2.55 | Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments. ( Almquist, J; Andersson, R; Chappel, MJ; Evans, ND; Gabrielsson, J; Jirstrand, M; Kroon, T; Oakes, ND, 2017) |
| "Niacin treatment after mild TBI inhibited trauma-induced production of reactive oxygen derivatives and elevated the anti-inflammatory IL-10 level." | 1.91 | Anti-Inflammatory, Antioxidant and Neuroprotective Effects of Niacin on Mild Traumatic Brain Injury in Rats. ( Akakin, D; Bektasoglu, PK; Erzik, C; Gurer, B; Koroglu, AK; Koyuncuoglu, T; Ozaydin, D; Ozkaya, SC; Yegen, BC; Yuksel, M, 2023) |
| "Niacin serves as a high-affinity ligand for the receptor HCAR2 (GPR109A)." | 1.72 | The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease. ( Casali, BT; Coronel, I; Lamb, BT; Landreth, GE; Lasagna-Reeves, CA; Lin, PB; Martinez, P; Moutinho, M; Oblak, AL; Puntambekar, SS; Tsai, AP, 2022) |
| "Maternal obesity is associated with multiple adverse reproductive outcomes, whereas the underlying molecular mechanisms are still not fully understood." | 1.62 | NAMPT reduction-induced NAD ( Ge, J; Gu, L; Liu, Y; Wang, H; Wang, Q; Wu, X; Zhu, S, 2021) |
| " Equimolar Glu + NA + NAC dosing in a zebrafish vertebrate model of rotenone-based complex I inhibition synergistically rescued larval activity, brain death, lactate, ATP and glutathione levels." | 1.62 | Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease. ( Bennett, M; Falk, MJ; Guha, S; Konkwo, C; Kwon, YJ; Mathew, ND; Nakamaru-Ogiso, E; Ostrovsky, J; Polyak, E; Seiler, C; Xiao, R; Zhang, Z, 2021) |
| "Administration of niacin to treat premature ovarian failure (POF) in mouse models showed inhibition of follicular apoptosis under harmful conditions, such as radiation and chemotherapy damage, by markedly reducing cumulus cell apoptosis." | 1.48 | Niacin Inhibits Apoptosis and Rescues Premature Ovarian Failure. ( Sun, M; Wang, D; Wang, S; Wang, Y; Yao, Y; Yu, L, 2018) |
| "Malignant glioma is a formidable disease that commonly leads to death, mainly due to the invasion of tumor cells into neighboring tissues." | 1.46 | Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation. ( Christian, L; Li, J; Mei, S; Niu, H; Perfetto, M; Ping, Z; Qu, J; Shi, Y; Wei, S; Yang, X; Zhang, Q, 2017) |
| " The evaluation of the side effects present shortly after dosing in the rotarod test has revealed neurotoxicity of Nic-BZA with experimentally determined TD50 value of 188." | 1.43 | Protective action of nicotinic acid benzylamide in a variety of chemically-induced seizures in mice. ( Paruszewski, R; Świąder, K; Świąder, MJ; Turski, WA; Łuszczki, JJ, 2016) |
| "Niacin is a popular nutritional supplement known to reduce the risk of cardiovascular diseases by enhancing high-density lipoprotein levels." | 1.42 | Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice. ( Chan, LK; Leung, PS; Wong, TP, 2015) |
| "Niacin was administered 3 days before the ischemia through 7 days of reperfusion." | 1.42 | Niacin ameliorates kidney warm ischemia and reperfusion injury-induced ventricular dysfunction and oxidative stress and disturbance in mitochondrial metabolism in rats. ( Fu, YH; Tai, ST; Wang, JJ; Yang, YC, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD), a leading cause of liver damage, comprises a spectrum of liver abnormalities including the early fat deposition in the liver (hepatic steatosis) and advanced nonalcoholic steatohepatitis." | 1.40 | Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML; Kukes, GD; Lambrecht, N, 2014) |
| "Niaspan treatment of stroke increases vascular stabilization, decreases brain hemorrhage and blood-brain-barrier (BBB) leakage in T1DM rats." | 1.39 | Niaspan attenuates the adverse effects of bone marrow stromal cell treatment of stroke in type one diabetic rats. ( Chen, J; Chopp, M; Lu, M; Ning, R; Roberts, C; Venkat, P; Yan, T; Ye, X; Zacharek, A, 2013) |
| "Niacin deficiency causes dramatic genomic instability in bone marrow cells in an in vivo rat model." | 1.38 | Niacin status and genomic instability in bone marrow cells; mechanisms favoring the progression of leukemogenesis. ( Kirkland, JB, 2012) |
| "Niacin treatment of PCN significantly increased Ang1 expression under high glucose condition." | 1.38 | Niaspan increases axonal remodeling after stroke in type 1 diabetes rats. ( Buller, B; Chen, J; Chopp, M; Cui, Y; Liu, Z; Roberts, C; Yan, T; Ye, X; Zacharek, A, 2012) |
| "T1DM-rats were subjected to transient middle cerebral artery occlusion (MCAo) and treated without or with Niaspan." | 1.37 | Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats. ( Chen, J; Chopp, M; Cui, X; Cui, Y; Liu, X; Lu, M; Roberts, C; Shehadah, A; Yan, T; Ye, X; Zacharek, A, 2011) |
| "We investigated the treatment of experimental autoimmune encephalomyelitis (EAE) in mice with Niaspan, an agent used to elevate high-density lipoprotein (HDL)." | 1.35 | Niaspan treatment improves neurological functional recovery in experimental autoimmune encephalomyelitis mice. ( Chen, J; Chopp, M; Cui, X; Elias, SB; Li, Y; Lu, M; Roberts, C; Zhang, J; Zheng, X, 2008) |
| "Niacin treatment significantly increased arterial sprouting and VSMC migration compared with control nontreated arterial cells." | 1.35 | Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke. ( Chen, J; Chopp, M; Cui, X; Ding, GL; Jiang, Q; Lu, M; Shehadah, A; Zacharek, A, 2009) |
| " The evaluation of time-course and dose-response relationships for iso-Nic-BZA provided evidence that the compound produced the peak to maximum antielectroshock action and acute adverse effects at 5min after its systemic (i." | 1.34 | Characterization of the anticonvulsant profile of isonicotinic acid benzylamide in various experimental seizure models in mice. ( Czuczwar, SJ; Luszczki, JJ; Paruszewski, R; Swiader, K; Swiader, MJ; Turski, WA, 2007) |
| "Taurine and niacin treatment significantly reduced the numbers of neutrophils, lymphocytes, and macrophages in the BL + TN group and caused significant reductions in BL-induced increases in the lung hydroxyproline content at 14 and 21 days in the BL + TN group." | 1.31 | Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. ( Giri, SN; Gurujeyalakshmi, G; Wang, Y, 2000) |
| "Experimental hyperlipidemia was induced in ddY, C57BL, BALB and ICR strain mice and in Wistar rats." | 1.27 | [Strains and species differences in experimental hyperlipidemia]. ( Hirai, Y; Kawakami, M; Koyama, S; Mishima, Y; Mizutani, A; Morishita, S; Saito, T, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (8.70) | 18.7374 |
| 1990's | 5 (5.43) | 18.2507 |
| 2000's | 21 (22.83) | 29.6817 |
| 2010's | 42 (45.65) | 24.3611 |
| 2020's | 16 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Y | 1 |
| Zhang, Y | 1 |
| Li, Y | 2 |
| Cheng, J | 1 |
| Chen, S | 1 |
| Xiao, Y | 1 |
| Ao, G | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zheng, Y | 1 |
| Chen, ZY | 1 |
| Ma, WJ | 1 |
| Wang, QZ | 1 |
| Liang, H | 1 |
| Ma, AG | 1 |
| Wang, H | 1 |
| Zhu, S | 1 |
| Wu, X | 1 |
| Liu, Y | 1 |
| Ge, J | 1 |
| Wang, Q | 1 |
| Gu, L | 1 |
| Moutinho, M | 1 |
| Puntambekar, SS | 1 |
| Tsai, AP | 1 |
| Coronel, I | 1 |
| Lin, PB | 1 |
| Casali, BT | 1 |
| Martinez, P | 1 |
| Oblak, AL | 1 |
| Lasagna-Reeves, CA | 1 |
| Lamb, BT | 1 |
| Landreth, GE | 1 |
| Ibrahim, WW | 1 |
| Sayed, RH | 1 |
| Kandil, EA | 1 |
| Wadie, W | 3 |
| Ozaydin, D | 1 |
| Bektasoglu, PK | 1 |
| Koyuncuoglu, T | 1 |
| Ozkaya, SC | 1 |
| Koroglu, AK | 1 |
| Akakin, D | 1 |
| Erzik, C | 1 |
| Yuksel, M | 1 |
| Yegen, BC | 1 |
| Gurer, B | 1 |
| Mohamed, SS | 1 |
| Abd El-Haleim, EA | 1 |
| Khayyal, MT | 1 |
| Horimatsu, T | 1 |
| Blomkalns, AL | 1 |
| Ogbi, M | 1 |
| Moses, M | 1 |
| Kim, D | 1 |
| Patel, S | 1 |
| Gilreath, N | 1 |
| Reid, L | 1 |
| Benson, TW | 1 |
| Pye, J | 1 |
| Ahmadieh, S | 1 |
| Thompson, A | 1 |
| Robbins, N | 1 |
| Mann, A | 1 |
| Edgell, A | 1 |
| Benjamin, S | 1 |
| Stansfield, BK | 1 |
| Huo, Y | 1 |
| Fulton, DJ | 1 |
| Agarwal, G | 1 |
| Singh, N | 1 |
| Offermanns, S | 2 |
| Weintraub, NL | 1 |
| Kim, HW | 1 |
| Yao, KX | 1 |
| Lyu, H | 1 |
| Liao, MH | 1 |
| Yang, L | 1 |
| Gao, YP | 1 |
| Liu, QB | 1 |
| Wang, CK | 1 |
| Lu, YM | 1 |
| Jiang, GJ | 1 |
| Han, F | 1 |
| Wang, P | 1 |
| Motawi, TK | 1 |
| Sadik, NAH | 1 |
| Hamed, MA | 1 |
| Ali, SA | 1 |
| Khalil, WKB | 1 |
| Ahmed, YR | 1 |
| Jiang, Y | 1 |
| Jin, M | 1 |
| Chen, J | 9 |
| Yan, J | 1 |
| Liu, P | 1 |
| Yao, M | 1 |
| Cai, W | 1 |
| Pi, R | 1 |
| Lewis, MJ | 1 |
| Guha, S | 1 |
| Mathew, ND | 1 |
| Konkwo, C | 1 |
| Ostrovsky, J | 1 |
| Kwon, YJ | 1 |
| Polyak, E | 1 |
| Seiler, C | 1 |
| Bennett, M | 1 |
| Xiao, R | 1 |
| Zhang, Z | 1 |
| Nakamaru-Ogiso, E | 1 |
| Falk, MJ | 1 |
| Asadi, N | 1 |
| Izadi, M | 1 |
| Aflatounian, A | 1 |
| Esmaeili-Dehaj, M | 1 |
| Rezvani, ME | 1 |
| Hafizi, Z | 1 |
| Hosseini, L | 1 |
| Mahmoudi, J | 1 |
| Pashazadeh, F | 1 |
| Salehi-Pourmehr, H | 1 |
| Sadigh-Eteghad, S | 1 |
| Natsumi, S | 1 |
| Kuroita, T | 1 |
| Ishikawa, T | 1 |
| Kuronuma, K | 1 |
| Yoshioka, T | 1 |
| Furtado, ABV | 1 |
| Gonçalves, DF | 1 |
| Hartmann, DD | 1 |
| Courtes, AA | 1 |
| Cassol, G | 1 |
| Nunez-Figueredo, Y | 3 |
| Argolo, DS | 1 |
| do Nascimento, RP | 1 |
| Costa, SL | 2 |
| da Silva, VDA | 1 |
| Royes, LFF | 1 |
| Soares, FAA | 1 |
| Salem, HA | 1 |
| Shi, H | 1 |
| Enriquez, A | 1 |
| Rapadas, M | 1 |
| Martin, EMMA | 1 |
| Wang, R | 1 |
| Moreau, J | 1 |
| Lim, CK | 1 |
| Szot, JO | 1 |
| Ip, E | 1 |
| Hughes, JN | 1 |
| Sugimoto, K | 1 |
| Humphreys, DT | 1 |
| McInerney-Leo, AM | 1 |
| Leo, PJ | 1 |
| Maghzal, GJ | 1 |
| Halliday, J | 1 |
| Smith, J | 1 |
| Colley, A | 1 |
| Mark, PR | 1 |
| Collins, F | 1 |
| Sillence, DO | 1 |
| Winlaw, DS | 1 |
| Ho, JWK | 1 |
| Guillemin, GJ | 1 |
| Brown, MA | 2 |
| Kikuchi, K | 1 |
| Thomas, PQ | 1 |
| Stocker, R | 1 |
| Giannoulatou, E | 1 |
| Chapman, G | 1 |
| Duncan, EL | 1 |
| Sparrow, DB | 1 |
| Dunwoodie, SL | 1 |
| Lee, SY | 1 |
| Bae, CS | 1 |
| Seo, JH | 1 |
| Cho, SS | 1 |
| Bae, MS | 1 |
| Oh, DS | 1 |
| Park, DH | 1 |
| Liu, J | 1 |
| Gao, W | 1 |
| Pu, L | 1 |
| Wei, J | 1 |
| Xin, Z | 1 |
| Wang, Y | 3 |
| Shi, T | 1 |
| Guo, C | 1 |
| Evans, E | 1 |
| Piccio, L | 1 |
| Cross, AH | 1 |
| Kwon, WY | 3 |
| Suh, GJ | 3 |
| Kim, KS | 3 |
| Jung, YS | 2 |
| Kim, SH | 1 |
| Lee, AR | 1 |
| You, KM | 1 |
| Park, MJ | 1 |
| Wang, S | 1 |
| Sun, M | 1 |
| Yu, L | 1 |
| Yao, Y | 1 |
| Wang, D | 1 |
| Wong-Guerra, M | 1 |
| Jiménez-Martin, J | 1 |
| Fonseca-Fonseca, LA | 1 |
| Ramírez-Sánchez, J | 2 |
| Montano-Peguero, Y | 1 |
| Rocha, JB | 1 |
| D Avila, F | 1 |
| de Assis, AM | 1 |
| Souza, DO | 2 |
| Pardo-Andreu, GL | 2 |
| Del Valle, RM | 1 |
| Lopez, GA | 1 |
| Martínez, OV | 1 |
| García, NM | 1 |
| Mondelo-Rodríguez, A | 1 |
| Padrón-Yaquis, AS | 1 |
| Periyasamy, S | 1 |
| John, S | 1 |
| Padmavati, R | 1 |
| Rajendren, P | 1 |
| Thirunavukkarasu, P | 1 |
| Gratten, J | 1 |
| Vinkhuyzen, A | 1 |
| McRae, A | 1 |
| Holliday, EG | 1 |
| Nyholt, DR | 1 |
| Nancarrow, D | 1 |
| Bakshi, A | 1 |
| Hemani, G | 1 |
| Nertney, D | 1 |
| Smith, H | 1 |
| Filippich, C | 1 |
| Patel, K | 1 |
| Fowdar, J | 1 |
| McLean, D | 1 |
| Tirupati, S | 1 |
| Nagasundaram, A | 1 |
| Gundugurti, PR | 1 |
| Selvaraj, K | 1 |
| Jegadeesan, J | 1 |
| Jorde, LB | 1 |
| Wray, NR | 1 |
| Suetani, R | 1 |
| Giacomotto, J | 1 |
| Thara, R | 1 |
| Mowry, BJ | 1 |
| Ferreira, RG | 2 |
| Matsui, TC | 1 |
| Gomides, LF | 1 |
| Godin, AM | 2 |
| Menezes, GB | 1 |
| de Matos Coelho, M | 1 |
| Klein, A | 1 |
| Sugita, K | 1 |
| Ikenouchi-Sugita, A | 1 |
| Nakayama, Y | 1 |
| Yoshioka, H | 1 |
| Nomura, T | 1 |
| Sakabe, J | 1 |
| Nakahigashi, K | 1 |
| Kuroda, E | 1 |
| Uematsu, S | 1 |
| Nakamura, J | 1 |
| Akira, S | 1 |
| Nakamura, M | 1 |
| Narumiya, S | 1 |
| Miyachi, Y | 1 |
| Tokura, Y | 1 |
| Kabashima, K | 1 |
| Yan, T | 3 |
| Ye, X | 3 |
| Chopp, M | 8 |
| Zacharek, A | 6 |
| Ning, R | 1 |
| Venkat, P | 1 |
| Roberts, C | 7 |
| Lu, M | 6 |
| Ganji, SH | 1 |
| Kukes, GD | 1 |
| Lambrecht, N | 1 |
| Kashyap, ML | 1 |
| Kamanna, VS | 1 |
| van den Hoek, AM | 1 |
| van der Hoorn, JW | 2 |
| Maas, AC | 1 |
| van den Hoogen, RM | 1 |
| van Nieuwkoop, A | 1 |
| Droog, S | 1 |
| Offerman, EH | 1 |
| Pieterman, EJ | 1 |
| Havekes, LM | 2 |
| Princen, HM | 3 |
| Chauke, CG | 1 |
| Arieff, Z | 1 |
| Kaur, M | 1 |
| Seier, JV | 1 |
| Hansel, G | 1 |
| Simões Pires, EN | 1 |
| Merino, N | 1 |
| Valdes, O | 1 |
| Delgado-Hernández, R | 1 |
| Parra, AL | 1 |
| Ochoa-Rodríguez, E | 1 |
| Verdecia-Reyes, Y | 1 |
| Salbego, C | 1 |
| Clifton, HL | 2 |
| Inceoglu, B | 1 |
| Ma, L | 1 |
| Zheng, J | 1 |
| Schaefer, S | 2 |
| Chen, L | 1 |
| So, WY | 1 |
| Li, SY | 1 |
| Cheng, Q | 1 |
| Boucher, BJ | 1 |
| Leung, PS | 2 |
| Schwaninger, M | 1 |
| Tai, ST | 1 |
| Fu, YH | 1 |
| Yang, YC | 1 |
| Wang, JJ | 1 |
| Jeong, KY | 1 |
| Kye, YC | 1 |
| Wong, TP | 1 |
| Chan, LK | 1 |
| Shibata, K | 3 |
| Świąder, MJ | 2 |
| Łuszczki, JJ | 1 |
| Paruszewski, R | 2 |
| Świąder, K | 2 |
| Turski, WA | 2 |
| Bolino, A | 1 |
| Piguet, F | 1 |
| Alberizzi, V | 1 |
| Pellegatta, M | 1 |
| Rivellini, C | 1 |
| Guerrero-Valero, M | 1 |
| Noseda, R | 1 |
| Brombin, C | 1 |
| Nonis, A | 1 |
| D'Adamo, P | 1 |
| Taveggia, C | 1 |
| Previtali, SC | 1 |
| Andersson, R | 1 |
| Kroon, T | 1 |
| Almquist, J | 1 |
| Jirstrand, M | 1 |
| Oakes, ND | 1 |
| Evans, ND | 1 |
| Chappel, MJ | 1 |
| Gabrielsson, J | 1 |
| Li, J | 3 |
| Qu, J | 1 |
| Shi, Y | 1 |
| Perfetto, M | 1 |
| Ping, Z | 1 |
| Christian, L | 1 |
| Niu, H | 1 |
| Mei, S | 1 |
| Zhang, Q | 1 |
| Yang, X | 1 |
| Wei, S | 1 |
| de Haan, W | 1 |
| Berbée, JF | 1 |
| Jukema, JW | 1 |
| Rensen, PC | 1 |
| Zhang, J | 1 |
| Cui, X | 5 |
| Zheng, X | 1 |
| Elias, SB | 1 |
| Watts, GF | 1 |
| Chan, DC | 1 |
| McNamara, DB | 1 |
| Murthy, SN | 1 |
| Fonseca, AN | 1 |
| Desouza, CV | 1 |
| Kadowitz, PJ | 1 |
| Fonseca, VA | 1 |
| Ding, GL | 1 |
| Shehadah, A | 4 |
| Jiang, Q | 1 |
| Cho, KH | 1 |
| Kim, HJ | 1 |
| Rodriguez-Iturbe, B | 1 |
| Vaziri, ND | 1 |
| Wu, BJ | 1 |
| Yan, L | 1 |
| Charlton, F | 1 |
| Witting, P | 1 |
| Barter, PJ | 1 |
| Rye, KA | 1 |
| Cui, Y | 3 |
| Ion, M | 1 |
| Kapke, A | 2 |
| Kwak, YH | 1 |
| Kapoor, A | 1 |
| Thiemermann, C | 1 |
| Liu, X | 1 |
| Kirkland, JB | 4 |
| Liu, Z | 1 |
| Buller, B | 1 |
| Ferreira, WC | 1 |
| Rocha, LT | 1 |
| Paiva, AL | 1 |
| Merlo, LA | 1 |
| Nascimento, EB | 1 |
| Bastos, LF | 1 |
| Coelho, MM | 1 |
| Inceoglu, AB | 1 |
| Yang, J | 3 |
| Hegedus, C | 1 |
| Hammock, BD | 1 |
| Lee, ST | 1 |
| Chu, K | 1 |
| Jung, KH | 1 |
| Kim, JH | 1 |
| Huh, JY | 1 |
| Yoon, H | 1 |
| Park, DK | 1 |
| Lim, JY | 1 |
| Kim, JM | 1 |
| Jeon, D | 1 |
| Ryu, H | 1 |
| Lee, SK | 1 |
| Kim, M | 1 |
| Roh, JK | 1 |
| Nassar, MA | 1 |
| Eldien, HM | 1 |
| Tawab, HS | 1 |
| Saleem, TH | 1 |
| Omar, HM | 1 |
| Nassar, AY | 1 |
| Hussein, MR | 1 |
| Terakata, M | 1 |
| Fukuwatari, T | 1 |
| Sano, M | 1 |
| Nakao, N | 1 |
| Sasaki, R | 1 |
| Fukuoka, S | 1 |
| Hwang, YC | 1 |
| Bakr, S | 1 |
| Ramasamy, R | 1 |
| Bergmann, SR | 1 |
| Vinson, JA | 1 |
| Mandarano, MA | 1 |
| Shuta, DL | 1 |
| Bagchi, M | 1 |
| Bagchi, D | 1 |
| Spronck, JC | 2 |
| Bartleman, AP | 1 |
| Boyonoski, AC | 2 |
| Giri, SN | 4 |
| Atac, IA | 1 |
| Peksel, A | 1 |
| Yanardag, R | 1 |
| Sokmen, BB | 1 |
| Doger, MM | 1 |
| Bilen, ZG | 1 |
| Thorn, SL | 1 |
| Young, GS | 1 |
| Zhao, SP | 2 |
| Dong, SZ | 2 |
| Wu, ZH | 2 |
| Luszczki, JJ | 1 |
| Czuczwar, SJ | 1 |
| Jiang, H | 1 |
| Zhang, C | 1 |
| Feldkamp, CS | 1 |
| Nampurath, GK | 1 |
| Mathew, SP | 1 |
| Khanna, V | 1 |
| Zachariah, RT | 1 |
| Kanji, S | 1 |
| Chamallamudi, MR | 1 |
| Papaliodis, D | 1 |
| Boucher, W | 1 |
| Kempuraj, D | 1 |
| Theoharides, TC | 1 |
| Carpenter, KJ | 1 |
| Blaisdell, RJ | 1 |
| Schiedt, MJ | 1 |
| Nagai, A | 1 |
| Yasui, S | 1 |
| Ozawa, Y | 1 |
| Uno, H | 1 |
| Konno, K | 1 |
| Marugami, M | 1 |
| Kondo, T | 1 |
| Gurujeyalakshmi, G | 2 |
| Hollinger, MA | 1 |
| Krause, BR | 1 |
| Turenne, SD | 1 |
| Seeman, M | 1 |
| Ross, BM | 1 |
| Gallacher, LM | 1 |
| Jacobs, RM | 1 |
| Shah, GM | 1 |
| Poirier, GG | 1 |
| Aikawa, H | 1 |
| Suzuki, K | 1 |
| Olivier, P | 1 |
| Plancke, MO | 1 |
| Marzin, D | 1 |
| Clavey, V | 1 |
| Sauzieres, J | 1 |
| Fruchart, JC | 1 |
| Morishita, S | 1 |
| Saito, T | 1 |
| Mishima, Y | 1 |
| Mizutani, A | 1 |
| Hirai, Y | 1 |
| Koyama, S | 1 |
| Kawakami, M | 1 |
| Winkelmann, RK | 1 |
| Johnson, GL | 1 |
| Ehrreich, SJ | 1 |
| el-Hage, AN | 1 |
| Balazs, T | 1 |
| Lynn, MD | 1 |
| Gross, MD | 1 |
| Shapiro, B | 1 |
| Bassett, D | 1 |
| Sebrell, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjuvant Effects of Vitamin A and Vitamin D Supplementation on Treatment of Children With ADHD:A Randomized, Double Blind, Placebo-controlled, Multicentric Trial.[NCT04284059] | Phase 4 | 504 participants (Anticipated) | Interventional | 2021-02-25 | Recruiting | ||
| Soluble Fms-like Tyrosine Kinase-1, Proangiogenic Protein Placental Growth Factor, and Niacin Levels in Women With Premature Ovarian Insufficiency[NCT04641624] | 90 participants (Actual) | Observational | 2020-11-20 | Completed | |||
| Research of Olfactory Neuroepithelial Tissue as a Potential Biomarker of Alzheimer Disease[NCT02129452] | 40 participants (Actual) | Observational | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for niacin and Disease Models, Animal
| Article | Year |
|---|---|
Alcoholism and nutrition: a review of vitamin supplementation and treatment.
Topics: Alcoholism; Animals; Avitaminosis; Dietary Supplements; Disease Models, Animal; Humans; Niacin; Nutr | 2020 |
Protective Effects of Nicotinamide Adenine Dinucleotide and Related Precursors in Alzheimer's Disease: A Systematic Review of Preclinical Studies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Apoptosis; Behavior, An | 2021 |
Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review.
Topics: Acetylcarnitine; Animals; Ascorbic Acid; Biotin; Caffeine; Creatine; Curcumin; Dietary Supplements; | 2018 |
Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation.
Topics: 3-Hydroxybutyric Acid; Adenylyl Cyclases; Animals; Brain; Brain Ischemia; Diet, Ketogenic; Dimethyl | 2015 |
Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acids, None | 2017 |
Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention.
Topics: Animals; Biguanides; Catheterization; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Di | 2009 |
The relationship of pellagra to corn and the low availability of niacin in cereals.
Topics: Animals; Biological Assay; Disease Models, Animal; Edible Grain; Europe; Humans; Niacin; Nutritive V | 1983 |
Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?
Topics: Animals; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipide | 1998 |
84 other studies available for niacin and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel hydrogen sulfide releasing nicotinic acid derivatives.
Topics: Animals; Brain Ischemia; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationshi | 2016 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
B Vitamins Supplementation Can Improve Cognitive Functions and May Relate to the Enhancement of Transketolase Activity in A Rat Model of Cognitive Impairment Associated with High-fat Diets.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Dietary Supplements; Disease Models, Animal; Folic A | 2021 |
NAMPT reduction-induced NAD
Topics: Animals; Cytokines; Diet, High-Fat; Disease Models, Animal; Embryonic Development; Female; Gene Knoc | 2021 |
The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Disease Progression; Mice | 2022 |
Niacin mitigates blood-brain barrier tight junctional proteins dysregulation and cerebral inflammation in ketamine rat model of psychosis: Role of GPR109A receptor.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Encephalitis; Hypolipidemic Agents; Ketamine; | 2022 |
Anti-Inflammatory, Antioxidant and Neuroprotective Effects of Niacin on Mild Traumatic Brain Injury in Rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Brain Concussion; Brain Injuries; Brain Injuries, T | 2023 |
Niacin modulates depressive-like behavior in experimental colitis through GPR109A-dependent mechanisms.
Topics: Animals; Benzilates; Colitis; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Niacin; Rat | 2023 |
Niacin protects against abdominal aortic aneurysm formation via GPR109A independent mechanisms: role of NAD+/nicotinamide.
Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Calcium Chloride; Cells, Cult | 2020 |
Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia.
Topics: Amlodipine; Animals; Astrocytes; Blood Vessels; Dementia, Vascular; Disease Models, Animal; Mice; Mi | 2019 |
Potential therapeutic effects of antagonizing adenosine A
Topics: Adenosine A2 Receptor Antagonists; Animals; Curcumin; Disease Models, Animal; Hippocampus; Humans; M | 2020 |
Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects.
Topics: Animals; Atherosclerosis; Cell Line; Cricetulus; Dimerization; Disease Models, Animal; Drug Design; | 2020 |
Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease.
Topics: Acetylcysteine; Animals; Caenorhabditis elegans; Disease Models, Animal; Drug Synergism; Electron Tr | 2021 |
Chronic niacin administration ameliorates ovulation, histological changes in the ovary and adiponectin concentrations in a rat model of polycystic ovary syndrome.
Topics: Adiponectin; Administration, Oral; Animals; Disease Models, Animal; Female; Niacin; Organ Size; Ovar | 2021 |
Effect of niacin supplementation on nausea-like behaviour in an isoniazid-induced mouse model of pellagra.
Topics: Animals; Dietary Supplements; Disease Models, Animal; Isoniazid; Mice; Nausea; Niacin; Pellagra; Pic | 2022 |
JM-20 Treatment After Mild Traumatic Brain Injury Reduces Glial Cell Pro-inflammatory Signaling and Behavioral and Cognitive Deficits by Increasing Neurotrophin Expression.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Benzodiazepines; Brain Concussion; Cognition; C | 2021 |
Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis.
Topics: Animals; Biomarkers; Biopsy; Body Weight; Colitis, Ulcerative; Cytokines; Disease Models, Animal; In | 2017 |
NAD Deficiency, Congenital Malformations, and Niacin Supplementation.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; Anal Canal; Animals; Congenital Abnormalities; Dietary Supple | 2017 |
Mycoleptodonoides aitchisonii suppresses asthma via Th2 and Th1 cell regulation in an ovalbumin‑induced asthma mouse model.
Topics: Agaricales; Animals; Anti-Asthmatic Agents; Asthma; Biological Products; Cytokines; Disease Models, | 2018 |
Modulation of hepatic gene expression profiles by vitamin B
Topics: Acute Disease; Animals; Dietary Supplements; Disease Models, Animal; Energy Metabolism; Gene Express | 2018 |
Niacin and Selenium Attenuate Brain Injury After Cardiac Arrest in Rats by Up-Regulating DJ-1-Akt Signaling.
Topics: Animals; Brain Injuries; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione; Hear | 2018 |
Niacin Inhibits Apoptosis and Rescues Premature Ovarian Failure.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cyclophosphamide; DEAD-box RNA Helicases; Disease Models | 2018 |
JM-20 protects memory acquisition and consolidation on scopolamine model of cognitive impairment.
Topics: Acetylcholinesterase; Animals; Antioxidants; Benzodiazepines; Brain; Cholinesterase Inhibitors; Cogn | 2019 |
Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study.
Topics: Adult; Animals; Case-Control Studies; Cell Line, Tumor; Chromosomes, Human, Pair 8; Disease Models, | 2019 |
Niacin inhibits carrageenan-induced neutrophil migration in mice.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Cell Adhesion; Chemokine CXCL1; Disease Models, Anim | 2013 |
Prostaglandin E₂ is critical for the development of niacin-deficiency-induced photosensitivity via ROS production.
Topics: 6-Aminonicotinamide; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dermatitis; Dinoproston | 2013 |
Niaspan attenuates the adverse effects of bone marrow stromal cell treatment of stroke in type one diabetic rats.
Topics: Animals; Blood-Brain Barrier; Diabetes Mellitus, Type 1; Disease Models, Animal; Ectodysplasins; Int | 2013 |
Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Disease Progression; Fatty | 2014 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol E | 2014 |
Effects of short-term niacin treatment on plasma lipoprotein concentrations in African green monkeys (Chlorocebus aethiops).
Topics: Analysis of Variance; Animals; Apolipoprotein A-I; Body Weight; Chlorocebus aethiops; Cholesterol, H | 2014 |
A novel multi-target ligand (JM-20) protects mitochondrial integrity, inhibits brain excitatory amino acid release and reduces cerebral ischemia injury in vitro and in vivo.
Topics: Animals; Benzodiazepines; Brain; Brain Ischemia; Cell Death; Disease Models, Animal; Excitatory Amin | 2014 |
TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice.
Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Capsaicin; Disease Models, Animal; Fl | 2015 |
Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets.
Topics: Animals; Cell Line; Disease Models, Animal; Glucose; Hyperglycemia; Hypolipidemic Agents; Insulin; I | 2015 |
Niacin ameliorates kidney warm ischemia and reperfusion injury-induced ventricular dysfunction and oxidative stress and disturbance in mitochondrial metabolism in rats.
Topics: Acute Kidney Injury; Animals; Biomarkers; Blood Urea Nitrogen; Disease Models, Animal; Male; Mitocho | 2015 |
The therapeutic effect and mechanism of niacin on acute lung injury in a rat model of hemorrhagic shock: Down-regulation of the reactive oxygen species-dependent nuclear factor κB pathway.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Down-Regulation; Lung; | 2015 |
Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice.
Topics: Animals; Blood Glucose; Caco-2 Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Respon | 2015 |
True Niacin Deficiency in Quinolinic Acid Phosphoribosyltransferase (QPRT) Knockout Mice.
Topics: Animals; Disease Models, Animal; Mice, Inbred C57BL; Mice, Knockout; Mutation; NAD; Niacin; Nutritio | 2015 |
Protective action of nicotinic acid benzylamide in a variety of chemically-induced seizures in mice.
Topics: Animals; Anticonvulsants; Benzyl Compounds; Disease Models, Animal; Male; Memory Disorders; Memory, | 2016 |
Niacin-mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination.
Topics: ADAM17 Protein; Animals; Charcot-Marie-Tooth Disease; Disease Models, Animal; Mice; Mice, Knockout; | 2016 |
Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation.
Topics: Animals; Antineoplastic Agents; Cadherins; Cell Adhesion; Cell Movement; Disease Models, Animal; Gli | 2017 |
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
Topics: Animals; Apolipoprotein A-I; Apolipoprotein E3; Atherosclerosis; Bile; Cholesterol Ester Transfer Pr | 2008 |
Niaspan treatment improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
Topics: Animals; Cell Line, Transformed; Cell Proliferation; Cholesterol, HDL; Disease Models, Animal; Dose- | 2008 |
Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Cholesterol Ester Transfer Proteins | 2008 |
Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Brain; Cells, Cultured; Cerebrovascular Circulation; Delayed | 2009 |
Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.
Topics: Animals; Chemokine CCL2; Creatinine; Disease Models, Animal; Hypertension; Inflammation; Kidney Fail | 2009 |
Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids.
Topics: Animals; Anti-Inflammatory Agents; Aortic Diseases; Carotid Artery Diseases; Chemokine CCL2; Cyclic | 2010 |
Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome.
Topics: Amyloid beta-Protein Precursor; Animals; Axons; Brain; Brain Ischemia; Calcium-Binding Proteins; Del | 2010 |
Niaspan treatment induces neuroprotection after stroke.
Topics: Animals; Brain Infarction; Delayed-Action Preparations; Disease Models, Animal; Infarction, Middle C | 2010 |
Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-κB pathway.
Topics: Animals; Biopsy, Needle; Disease Models, Animal; Down-Regulation; Endotoxemia; Follow-Up Studies; Ge | 2011 |
Niacin as a novel therapy for septic shock?
Topics: Animals; Disease Models, Animal; Down-Regulation; Endotoxemia; Female; Humans; Male; NF-kappa B; Nia | 2011 |
Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats.
Topics: Angiotensin I; Angiotensin II; Animals; Blood Glucose; Blood-Brain Barrier; Cerebral Hemorrhage; Cer | 2011 |
Niacin status and genomic instability in bone marrow cells; mechanisms favoring the progression of leukemogenesis.
Topics: Animals; Avitaminosis; Bone Marrow Cells; Cell Transformation, Neoplastic; Disease Models, Animal; D | 2012 |
Niaspan increases axonal remodeling after stroke in type 1 diabetes rats.
Topics: Animals; Axons; Diabetes Mellitus, Type 1; Disease Models, Animal; Female; Infarction, Middle Cerebr | 2012 |
Nicotinic acid induces antinociceptive and anti-inflammatory effects in different experimental models.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Disease Models, Animal; E | 2012 |
Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice.
Topics: Animals; Arachidonic Acid; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2012 |
miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model.
Topics: Alzheimer Disease; Animals; Benzylamines; Brain; Brain-Derived Neurotrophic Factor; Dendritic Spines | 2012 |
Time-dependent morphological and biochemical changes following cutaneous thermal burn injury and their modulation by copper nicotinate complex: an animal model.
Topics: Animals; Biomarkers; Burns; Ceruloplasmin; Copper; Disease Models, Animal; Female; Free Radical Scav | 2012 |
Establishment of true niacin deficiency in quinolinic acid phosphoribosyltransferase knockout mice.
Topics: Animals; Body Weight; Disease Models, Animal; Eating; Mice; Mice, Inbred C57BL; Mice, Knockout; NAD; | 2012 |
Relative importance of enhanced glucose uptake versus attenuation of long-chain acyl carnitines in protecting ischemic myocardium.
Topics: Animals; Carnitine; Creatine Kinase; Cytochalasin B; Disease Models, Animal; Glucose; Models, Cardio | 2002 |
Beneficial effects of a novel IH636 grape seed proanthocyanidin extract and a niacin-bound chromium in a hamster atherosclerosis model.
Topics: Animals; Arteriosclerosis; Cholesterol; Chromium; Cricetinae; Disease Models, Animal; Grape Seed Ext | 2002 |
Chronic DNA damage and niacin deficiency enhance cell injury and cause unusual interactions in NAD and poly(ADP-ribose) metabolism in rat bone marrow.
Topics: Alkylating Agents; Animals; Bone Marrow Cells; Disease Models, Animal; DNA Damage; Dose-Response Rel | 2003 |
The combined treatment with taurine and niacin blocks the bleomycin-induced activation of nuclear factor-kappaB and lung fibrosis.
Topics: Animals; Base Sequence; Bleomycin; Blotting, Western; Bronchoalveolar Lavage Fluid; Cytokines; Disea | 2003 |
The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats.
Topics: Animals; Catalase; Chlorides; Cholesterol; Chromium Compounds; Dietary Fats; Disease Models, Animal; | 2006 |
The guinea-pig is a poor animal model for studies of niacin deficiency and presents challenges in any study using purified diets.
Topics: Animals; Bone Marrow; Caseins; Dietary Supplements; Disease Models, Animal; Gelatin; Guinea Pigs; Hu | 2007 |
Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits.
Topics: Adipocytes; Analysis of Variance; Animals; Anticholesteremic Agents; Biological Transport; Cholester | 2008 |
Characterization of the anticonvulsant profile of isonicotinic acid benzylamide in various experimental seizure models in mice.
Topics: Animals; Anticonvulsants; Behavior, Animal; Benzyl Compounds; Disease Models, Animal; Drug Interacti | 2007 |
Niaspan increases angiogenesis and improves functional recovery after stroke.
Topics: Angiopoietin-1; Animals; Bromodeoxyuridine; Cells, Cultured; Cholesterol; Cholesterol, HDL; Disease | 2007 |
[Effect of niacin on HDL-induced cholesterol efflux and LXRalpha expression in adipocytes of hypercholesterolemic rabbits].
Topics: Adipocytes; Animals; Cholesterol; Disease Models, Animal; DNA-Binding Proteins; Hypercholesterolemia | 2007 |
Assessment of hypolipidaemic activity of three thiazolidin-4-ones in mice given high-fat diet and fructose.
Topics: Administration, Oral; Animals; Blood Glucose; Cholesterol; Diet; Dietary Fats; Disease Models, Anima | 2008 |
The flavonoid luteolin inhibits niacin-induced flush.
Topics: Animals; Aspirin; Body Temperature; Disease Models, Animal; Flushing; Hypolipidemic Agents; Luteolin | 2008 |
Dietary supplementation with taurine and niacin prevents the increase in lung collagen cross-links in the multidose bleomycin hamster model of pulmonary fibrosis.
Topics: Animals; Bleomycin; Collagen; Cricetinae; Diet; Dipeptides; Disease Models, Animal; Male; Mesocricet | 1994 |
Niacin attenuates acute lung injury induced by lipopolysaccharide in the hamster.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cricetinae; Disease Models, Animal; Endotoxins; Escherichia c | 1994 |
In vivo inhibition of kynurenine aminotransferase activity by isonicotinic acid hydrazide in rats.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Enzyme Inhibitors; Isoniazid; Lyases; Male; | 1996 |
Regulation of transforming growth factor-beta1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis.
Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Collagen; Cricetinae; Diet; Disease Models, Animal | 1998 |
Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin.
Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Gene Expression Regulation | 2000 |
An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response.
Topics: Animals; Antipsychotic Agents; Brain; Caffeine; Cerebrovascular Circulation; Disease Models, Animal; | 2001 |
Niacin deficiency decreases bone marrow poly(ADP-ribose) and the latency of ethylnitrosourea-induced carcinogenesis in rats.
Topics: Alkylating Agents; Animals; Bone Marrow; Disease Models, Animal; Ethylnitrosourea; Male; Morbidity; | 2002 |
Lesions in the skin, intestine, and central nervous system induced by an antimetabolite of niacin.
Topics: 6-Aminonicotinamide; Animals; Animals, Suckling; Brain; Cytoplasm; Disease Models, Animal; Ependyma; | 1986 |
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofib | 1988 |
[Strains and species differences in experimental hyperlipidemia].
Topics: Animals; Clofibrate; Disease Models, Animal; Gemfibrozil; Glycerides; Hyperlipidemias; Hypolipidemic | 1986 |
Nicotinate white response of monkey sexual skin--a model for atopic reactivity.
Topics: Animals; Chlorocebus aethiops; Dermatitis, Contact; Disease Models, Animal; Macaca mulatta; Niacin; | 1986 |
Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Body Weight; Bretylium Tosylate; Death, Sudden; Disease Models, Ani | 1986 |
The influence of hypercholesterolaemia on the adrenal uptake and metabolic handling of 131I-6 beta-iodomethyl-19-norcholesterol (NP-59).
Topics: 19-Iodocholesterol; Adrenal Cortex; Animals; Bile; Cholesterol; Colestipol; Disease Models, Animal; | 1986 |
History of pellagra.
Topics: Animals; Disease Models, Animal; Dog Diseases; Dogs; History, 18th Century; History, 19th Century; H | 1981 |